Consolidated Financial Result Digest FY2020 Q2 (Fiscal Year Ending March 31, 2020)



November 1, 2019



Any information incorporated in this document is not intended for suggestion of purchase or sale of equity share of the company. All the description and projection are based on the company's own analysis at the time of compilation, and their accuracy is not guaranteed. These data may be revised without prior announcement. The company will neither assume nor compensate any loss of anybody resulting from decision based on information provided here.



Summary



Our Reporting Segments

Electronics Materials

Manufactures, stocks and markets chemicals for PWBs and other electronic components





Medical and Pharmaceuticals

Develops, manufactures, and markets pharmaceuticals and quasi-drugs





Other

Manufactures and markets dyes, pigments and other chemical products, supplies renewable energy, Software development





3 FY2020 Q2 Overview


- Uncertainty in the global economy has continued since last year due to trade friction between the U.S. and China
- Sales volume of dry film for PKG remained flat YoY while solder resist for the automotive declined
- Completed the acquisition of Taiyo Pharma Tech (Takatsuki Plant) on October 1st, 2019
- Taiyo Green Energy established new 5 solar power plants on water (10 plants in total)
- (System Subsidiary) Thou-Management Corporation: Adoption of [Verification test by utilizing QZSS (MICHIBIKI)]
- (System Subsidiary) Absorption-type of Merger of Thou-Management Corporation by MICRO NETWORK TECHNOLOGIES CORP. (November 1st)



FY2020 Q2 Topics

Established new floating solar power (10 plants in total)

10 plants are estimated to generate 16.1GWh on an annual basis, which is equivalent to 100% power consumption in our domestic group *Excluding Taiyo Pharma Tech




Apple Introduces Taiyo Ink as an Apple Supplier with 100 percent Renewable Energy

Website: Apple (Japan)
URL: https://www.apple.com/jp/job-creation/

: https://www.apple.com/jp/newsroom/2018/04

Outline: Adoption of Verification test by utilizing MICHIBIKI*

Thou-Management Corporation was adopted by "Verification test by utilizing MICHIBIKI in 2019" publicly sought by Cabinet Office and Quasi-Zenith Satellite System Services Inc. This adoption will be feasible to contribute to SDGs* focusing on the fields such as agriculture and infrastructure




*MICHIBIKI: Quasi-Zenith Satellite System (QZSS)

*MADOCA: MADOCA: Multi-GNSS Advanced Demonstration tool for Orbit and Clock Analysis

***SDGs:** Sustainable Development Goals



Absorption-type of Merger of Thou-Management Corporation by MICRO NETWORK TECHNOLOGIES CORP.



This absorption-type merger aims to utilize operating resources by integrating Thou-Management and MICRO NETWORK TECHNOLOGIES specialties and deepening and expanding their technologies

MICRO NETWORK TECHNOLOGIES aims to grow sustainably as a "Indispensable to the world" in line with changing market environment



FY2020 Q2 Consolidated Financial Results

Result Summary

Unit: JPY million


	FY2019 Q2	FY2020 Q2			FY2020 1H	Progress
	result	result	YoY	%	forecast	rate
Net sales	30,257	31,202	+945	+3%	32,600	96%
Operating income	5, 261	4,073	-1,188	-23%	4,300	95%
Ordinary income	5,214 [*]	3,928	-1,286	-25%	4,250	92%
Net income	3, 731	3,137	-594	-16%	3,000	105%
Exchange rate of JPY/USD	110.0	108.9			110.0	

X The provisional accounting for the business combination was confirmed at the end of the previous consolidated fiscal year and the results for the first quarter of fiscal year ended March 31, 2019 reflect the contents of the provisional accounting that was confirmed.





FY2020 Q2 Segment Information






Trend of Quarterly Performance

Net Sales & Operating Income

Unit: JPY million



Operating income (right axis)



BS (YoY)

JPY millions

	FY2019/3	FY2019/9	YoY
Cash and deposits	31,340	66,960	35,620
Accounts receivable - trade	16,610	17,714	1,104
Inventory assets [*]	8,446	7,958	-488
Other	1,740	1,209	-531
Total current assets	58,136	93,842	35,706
Property, plant and equipment	22,313	24,788	2,475
Intangible assets	21,436	20,853	-583
Other	3,779	4,084	305
Total non-current assets	47,529	49,726	2,197
Total assets	105,666	143,568	37,902

	FY2019/3	FY2019/9	YoY
Loans payable [*]	20,306	60,001	39,695
Notes and accounts payable - trade	6,285	6,787	502
Other	8,555	6,240	-2,315
Total liabilities	35,146	73,028	37,882
Capital stock	69,336	70,900	1,564
Other	846	-638	-1,484
Non-controlling interests	337	277	-60
Total net assets	70,520	70,539	19
Total liabilities and net assets	105,666	143,568	37,902

Equity ratio	66.4%	48.9%	-17.5%

X Loans payable: Short-term borrowings + Current portion of long-term borrowings + Long-term borrowings




 $[\]frak{\%}$ Inventory assets: Merchandise and finished goods + Work in process + Raw materials and supplies

11

FY2020 Q2 CF Highlights

CF (YoY)

JPY millions





FY2020 full year forecast

full year forecast

JPY millions

	FY2020 full year forecast previous		FY2020 full year forecast latest			Change				
	forecast (A)	Takatsuki Plant forecast	forecast (including Takatsuki Plant)	forecast	Takatsuki Plant forecast	forecast (including Takatsuki Plant) (B)	forecast	Takatsuki Plant forecast	forecast (including Takatsuki Plant)	forecast (B - A)
Net sales	65,000	7,500	72,500	62,500	8,500	71,000	-2,500	1,000	-1,500	6,000
Operating income	8,500	300	8,800	8,000	300	8,300	-500	0	-500	-200
Ordinary income	8,400	300	8,700	7,700	300	8,000	-700	0	-700	-400
Net income	5,900	200	6,100	5,950	450	6,400	50	250	300	500
Exchange rate of JPY/USD	110.0	_	110.0	108.9	_	108.9				



Electronics Materials Business

Term	Definition
PWB	Printed wiring boards
SR	"Solder resist ink" or "Solder mask"
PKG	Semiconductor packages
DF	Dry film



Classification of Product


Group	Category		Туре	Remarks		
	Rigid	high-end	. Liquid			
	Rigiu	regular	Liquid	•SR materials for insulation and surface		
PWB insulating materials	PKG		Liquid/Dry Film	protection use		
materials	FPC		Liquid/Dry Film			
	Build-up		Liquid/Dry Film	 build-up materials for interlayer insulation and hole plugging use 		
Other related products	Other		Liquid	marking, etching, plating materialsflux, solvent etc.conductive silver paste		




Electronics Materials Business

Sales Results by Product Group Category

JPY millions





*Since the product classification has been partially revised from FY2020, there is a difference from the figures disclosed in the past.





Medical and Pharmaceutical Business Strategy


Term	Definition
Long-listed drugs	drugs for which the patent has expired or the re-examination period has ended and there exist generic alternatives that have the same efficacy as the long-listed drug.
CDMO	Contract Development Manufacturing Organization
GMP	Good Manufacturing Practice



Sales, Operating Income, EBITDA

JPY millions





※EBITDA=operating profit + depreciation + Amortization of sales rights





Acquisition of Daiichi Sankyo Propharma Co., Ltd. Takatsuki Plant

Completed the acquisition of Takatsuki Plant with the goal of newly establishing an internal manufacturing center for 37.9 billion yen (acquisition value) on October 1st 2019





Outline of Takatsuki factory

Takatsuki Plant began operations in 1933. The plant produces solid preparations and injectable drugs under an advanced, GMP-compliant manufacturing and quality management structure

m **Head Office** Started operation Number of e m p l o y e e s Production member Number of shares issued Shareholder

TAIYO Pharma Tech Co., Ltd.

4-38, Aketacho, Takatsuki, Osaka 569-0806, Japan

Plant floor space: 52,584 m

December 25th ,1933

Approx. 330 (as of April 1st , 2019)

Solid preparations · Injectable drugs

President CEO Eiji Sato
Director Masato Mori
Director Suguru Ominato
Corporate Auditor Hidenori Sugiura

6,000 shares

Taiyo Holdings 100%




TAIYO HOLDINGS CO., LTD.

Takatsuki Plant continues to conduct the contracted manufacturing business from the Daiichi Sankyo Group. From now on, Takatsuki Plant aims to capture new drug manufacturing contracts from customers outside the Daiichi Sankyo Group and to leap to become a CDMO




FY2020 Q2 Topics

Relation to Taiyo Pharma Tech






Prospect of Medical and Pharmaceutical Business





Prospect of Medical and Pharmaceutical Business

We consider the medical and pharmaceutical business to be the second pillar of Taiyo HD. We are developing this with two businesses - the CDMO business that will take over the DNA of Daiichi Sankyo and the long-listed products business operated by Taiyo Pharma.



✓ Takeover (continue)
long-listed products

- ✓ Establish overseas plants
- ✓ Establish a formulation research institute
- ✓ Acquire a Japanese mother plant (Takatsuki Plant)



